Aortech Share Discussion Threads

[mustau] 29/1/2018 10:12

Mike
Do they have the funding?

[blueball] 29/1/2018 10:10

All buys today and share price treading water.

48p this week.

[mikeh30] 29/1/2018 09:31

https://3dprint.com/201338/funding-3d-print-polymer-platform/6million in funding

[turbotrader2] 28/1/2018 13:37

Some great posts. Thank you

[the stigologist] 28/1/2018 12:32

The potential here is incredible... start delivering on some of these and we should see 100p as a starting point for any rise

Outlook/Conclusion (from August 15th Final Results RNS)

"A new revenue-generating licence has been signed and enquiries have increased markedly. We have taken back control of our breast implant IP and are actively pursuing opportunities to exploit this alongside our other intellectual property, including heart valves and polymers."

[the stigologist] 28/1/2018 10:23

My research summary from prior to the litigation settlement and Interims
Surprised we are still below 100p frankly...

Aortech (AOR)

sp 22.5p
shares o/s 5.6m
mkt cap £1.2m

AorTech has developed biostable, implantable polymers, including Elast-Eonâ„¢ and ECSilâ„¢ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

Elast-Eonâ„¢ and ECSilâ„¢'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.

Financials
Revenue $614k
Profit $55k
Cash $114k

Upside ?
1. Change in licensing strategy
"Our manufacturing licensee, Biomerics concluded a licence for Elast-Eonâ„¢ earlier this year together with a long term supply agreement. There are currently a number of companies evaluating Elast-Eonâ„¢ which if succesful may lead to other licences. Biomerics adopts a different approach to licensing to that which AorTech has historically pursued. AorTech signed a number of licences with very small/development companies long before products were ready for market launch. As a result, other than annual maintenance fees, the revenues from those licences depended upon future product launches. By contrast, Biomerics is focussed on volume supply and near term success."

2.Additional licensing opportunities
Some historic licences signed by the Company have not generated value for AorTech and have only resulted in the Elast-Eonâ„¢ material not being exploited in the field of the licence. An example of this was the licence for breast implants signed in 2011. Since that time, AorTech's technology has not been incorporated into any new device nor generated any revenue for AorTech despite maintaining an IP portfolio in this arena. Your Board still believes there to be substantial benefits in utilising Elast-Eonâ„¢ technology in cosmetic and reconstructive surgery and as a result recently terminated this licence in order to pursue other opportunities in the field.

Outlook/Conclusion (from August 15th Final Results RNS)

"A new revenue-generating licence has been signed and enquiries have increased markedly. We have taken back control of our breast implant IP and are actively pursuing opportunities to exploit this alongside our other intellectual property, including heart valves and polymers."



-------------------------------

Interesting stakebuilding.

Former CEO who resigned in Oct 2016 went above 10% holding in Sept 2017

Litigation

They were suing another former CEO but looks like settlement on that soon. Just drawing a line under it should be positive.


---------------------------------

[the stigologist] 27/1/2018 22:26

FCA are chocolate teapots. They won't care and don't have the systems to monitor or enforce this.

UK regulatory system is principles based and 'self-regulated' which gives them huge leeway to just about do anything/nothing as it suits them.

[redbraces] 27/1/2018 20:05

The Stigologist

Well, I have over 3%. Not that I am complaining.

I havn't been asked to declare my holding.

Actually, looking to add.

[the stigologist] 27/1/2018 18:53

His antics will soil the reputation of any TR1 declaration for a while I expect

[turbotrader2] 27/1/2018 18:18

Yes but are you of the same ilk?

[the stigologist] 27/1/2018 17:09

Have you seen what went on in PYC last few days?

[turbotrader2] 27/1/2018 16:52

What have you got to lose? It will be a huge signal to the market-let's face it there is no free float

[turbotrader2] 27/1/2018 16:29

I'm still intrigued as to why Bill couldn't just shoot me a simple reply rather than say he will when he returns to the office He's up to something :-)

[the stigologist] 27/1/2018 11:20

I think they know they have a goldmine

Which is why they protected the equity

No placings, No lifestyle business salaries

That's the great thing about this Company, it's already profitable on current business

let alone with the built in expansion of their Biomerics partnership

let alone they start licensing their tech in other massive growth markets

[k1ngkonggb] 27/1/2018 11:17

Stig, let's hope so. Got Msys and some here but looking to plough more in here. Need some direction by the management as I think they're sitting on a goldmine.

[the stigologist] 27/1/2018 10:52

I have a bit of a dilemma here now. Close to 3% but would like to buy more because it looks so cheap on a risk-reward basis but don't want to have to declare by going over 3% threshold. Parsons is right this could be an easy ten bagger.

[the stigologist] 27/1/2018 10:42

Maybe. The flag/pennant which is a continuation pattern is coming to an end. It will move big one way or the other. But as flag/pennants are continuation patterns the odds heavily favour move to upside

(as of course do the fundamentals)

[blueball] 27/1/2018 10:12

The share is oversold at a 14 day low should bounce back next week to 48p.

[parsons4] 26/1/2018 22:31

The secret here is that there is no volume. This morning I was going to top up because I can't resist a bargain and I was going to sell some TAVI but there was no bid there so I left it. AOR at the time were being offered at just under 40p I could have bought 25k shares but then a few buyers came in and the price recovered !!
The point here is this is way under the radar. I just hope that the management know how to deal with the demand that is obviously out there for the product, if they do then this is a ten bagger !!! GLA

[the stigologist] 26/1/2018 18:54

50 day Moving Average rising rapidly to provide support (every day that goes by knocks out some of those 20p days from the averages)

News and Volume should see a big upside move from here

[bbr391] 26/1/2018 15:36

Looks like the conference may be Our time to shine.

Best of Luck Mr Brown et Al

[the stigologist] 26/1/2018 15:13

mikeh that guy has deleted all his posts so he's running scared i don't expect the spineless coward will be back any time soon

[the stigologist] 26/1/2018 15:12

Maybe. Only 6 full trading days before that Conference starts. You'd imagine it would be a good idea to reveal their Strategic Plan to Investors next week (maybe Roadshow it to Stockdale HNWI and Institutional Clients) and then the week after go and start executing on it/unveil some contracts/licensees at the Show.